A Part of the University of Maryland Medical Center

Connect with UMGCC
Facebook Twitter YouTube Blog iPhone
Email PageEmail page Print PagePrint page

55th American Society of Hematology (ASH) Annual Meeting

December 7-10, 2013

Experts from the University of Maryland Marlene and Stewart Greenebaum Cancer Center presented the following research findings at the 2013 ASH meeting in New Orleans, LA.

Oral presentations

Engineered T-Cells Expressing An HLA-Restricted Affinity-Enhanced TCR In Advanced Multiple Myeloma Patients Post Auto-SCT Engraft and Are Associated With Encouraging Post Auto-SCT Responses

Aaron P. Rapoport, MD1, Edward A. Stadtmauer, MD2, Dan T. Vogl, MD, MSCE3, Brendan M Weiss, MD3, Gwendolyn K. Binder-Scholl, PhD4, Dominic P. Smethurst, MD5*, Jeffrey Finklestein2*, Irina Kulikovskaya2*, Minnal Gupta2*, Joanna E. Brewer, PhD5*, Alan D. Bennett, PhD5*, Andrew B. Gerry, PhD5*, Nicholas J. Pumphrey, PhD5*, Helen K. Tayton-Martin, PhD5*, Lilliam C. Ribeiro, MBe4*, Ashraf Badros, MD6, Saul Yanovich, MD1, Gorgun Akpek, MD, MS1, Naseem Kerr, MPH2*, Sunita Philip1*, Sandra Westphal1*, Bruce L. Levine, PhD7, Bent K. Jakobsen, PhD5*, Michael Kalos, PhD2 and Carl H. June, MD2,7

C-MYC and C-MYC-Regulated MicroRNAs Increase The Activity Of The Error-Prone ALT NHEJ Pathway Through Upregulation Of LIG3 and PARP1 In Tyrosine Kinase-Activated Leukemias

Nidal E Muvarak, MS 1,2*, Shannon M Kelley, BS3*, Mario Tarasco3*, Maria R. Baer, MD2, Kara A. Scheibner, PhD3* and Feyruz Rassool, PhD1,2

Posters

Cytokine Alteration In Multiple Myeloma (MM) Patients and Bisphosphonate (BP)-Related Osteonecrosis Of The Jaw (BRONJ)

Ashraf Badros, MD1, Sunita Philip2*, Patricia Lesho3*, Mariola Sadowska4*, Dianna Weikel5*, Timothy Meiller5*, Rena Lapidus6*, Lisa Hester7*, Todd Milliron8* and Olga Goloubeva8*

Characteristics and Outcome Of Multiple Myeloma (MM) In African Americans (AA) Receiving Novel Agents and Autologous Stem Cell Transplantation (ASCT)

Vishal Bhatnagar, MD1, Yin Wu, MD1*, Olga Goloubeva2*, Kathleen Ruehle, RN1*, Todd Milliron2*, Saul Yanovich, MD1, Aaron P. Rapoport, MD3 and Ashraf Badros, MD4

Demethylating Agents Reprogram Myelodysplastic Syndrome and Leukemia Cells, Sensitizing Them To Poly-(ADP)-Ribose Polymerase Inhibitors

Carine Robert, PhD1*, Nidal E Muvarak, MS1*, Vu H. Duong, MD2, Maria R. Baer, MD3, Stephen B. Baylin, MD4* and Feyruz Rassool, PhD1

Dimeric Naphthoquinones: Novel Anti-Leukemic Agents Modulating Cellular Redox Status

Ashkan Emadi, M.D., Ph.D.1, Mariola Sadowska, PhD2*, Brandon Carter-Cooper, BS3*, Omasiri Wonodi, BS3*, Nidal Muvarak, BS2*, Feyruz Rassool, PhD4, Anil Jaiswal, PhD3*, Maria R. Baer, MD5, Rena G. Lapidus, PhD2* and Edward A. Sausville, MD, PhD6*

Synergistic Antileukemic Effect Of Sequential Administration Of Dichloroacetate (DCA) Combined With Arsenic Trioxide (ATO) In Primary Blasts From Patients With Acute Myeloid Leukemia (AML) and FLT3-ITD AML Cell Lines

Ashkan Emadi, M.D., Ph.D.1, Brandon Carter-Cooper, BS2*, Mariola Sadowska, PhD3*, Omasiri Wonodi, BS2*, Rena G. Lapidus, PhD3*, Mark Levis, MD, PhD4 and Edward A. Sausville, MD, PhD5*

Clinical Benefit Of Anticoagulation In Treatment Of Catheter-Related Deep Vein Thrombosis In Patients With Acute Leukemia

Briana Short, MD1*, Nora Oliver, MD1*, Mya S Thein, MD2*, Vu H. Duong, MD3, Michael L. Tidwell, C.R.N.P.3*, Edward A. Sausville, MD, PhD4*, Farin Kamangar, MD, PhD5*, Maria R. Baer, MD6 and Ashkan Emadi, M.D., Ph.D.7

MiR-144 and MiR-451 Regulate Human Erythropoiesis By Targeting RAB14

MinJung Kim, PhD1*, Yee Sun Tan1*, Wen-Chih Cheng, PhD1* and Curt I. Civin, M.D.1,2

Additional item

Dr. Maria Baer is an invited speaker in the 2014 Highlights of ASH in North America programs. These programs present an overview and an analysis of the highest-rated and most newsworthy abstracts and educational sessions from the 55th ASH Annual Meeting. Dr. Baer will speak on Acute Myeloid Leukemia.


This page was last updated on: December 27, 2013.